Cardiac,O
risk,O
factors,O
and,O
prevention,O
ORIGINAL,O
RESEARCH,O
Maria,PERSON
Elena,PERSON
Flacco,PERSON
.1,NUMBER
Cecilia,PERSON
Acuti,PERSON
Martellucci,PERSON
.2,O
Francesca,PERSON
Bravi,PERSON
.3,O
Giustino,PERSON
Parruti,O
.4,NUMBER
Rosaria,PERSON
Cappadona,PERSON
.1,O
Alfonso,PERSON
Mascitelli,PERSON
.5,O
Roberto,PERSON
Man,PERSON
‐,PERSON
fredini,O
.6,O
Lorenzo,PERSON
G,PERSON
Mantovani,PERSON
.7.8,O
Lamberto,PERSON
Manzoli,PERSON
1,NUMBER
Additional,O
material,O
is,O
Department,ORGANIZATION
of,ORGANIZATION
Medical,ORGANIZATION
Ferrara,ORGANIZATION
.,O
Emilia,O
‐,O
Ro,O
‐,O
magna,O
.,O
Italy,COUNTRY
Surgery,CAUSE_OF_DEATH
.,O
Ancona,PERSON
.,O
Marche,LOCATION
.,O
Italy,COUNTRY
Arcispedale,PERSON
SantAnna,PERSON
Medical,ORGANIZATION
Department,ORGANIZATION
.,O
Cona,PERSON
.,O
Emilia,O
‐,O
Romagna,LOCATION
.,O
Italy,COUNTRY
Infectious,O
Dis,O
‐,O
eases,O
Unit,O
.,O
Local,ORGANIZATION
Health,ORGANIZATION
Unit,ORGANIZATION
of,ORGANIZATION
Pescara,ORGANIZATION
.,O
Pescara,ORGANIZATION
.,O
Regional,O
Healthcare,ORGANIZATION
Agency,ORGANIZATION
of,O
Abruzzo,LOCATION
.,O
Pescara,ORGANIZATION
.,O
Italy,COUNTRY
Dipartimento,O
di,O
Scienze,O
Mediche,O
.,O
Universita,ORGANIZATION
degli,ORGANIZATION
Studi,ORGANIZATION
di,ORGANIZATION
Ferrara,ORGANIZATION
.,O
Ferrara,PERSON
.,O
Italy,ORGANIZATION
Center,ORGANIZATION
for,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
Bicocca,ORGANIZATION
.,O
Milano,LOCATION
.,O
Lombardia,CITY
.,O
IRCCS,O
MultiMedica,O
.,O
Sesto,PERSON
San,PERSON
Giovanni,PERSON
.,O
Lombardia,CITY
.,O
Italy,COUNTRY
Correspondence,O
to,O
Professor,TITLE
Lamberto,PERSON
Manzoli,PERSON
.,O
Ferrara,PERSON
.,O
Ferrara,PERSON
44121,NUMBER
.,O
Italy,COUNTRY
;,O
MEF,O
and,O
CAM,ORGANIZATION
contributed,O
Revised,O
9,DATE
June,DATE
2020,DATE
Objective,O
It,O
has,O
been,O
hy,O
‐,O
pothesised,O
that,O
the,O
use,O
of,O
ACE,O
inhibitors,O
and,O
angiotensin,O
recep,O
‐,O
tor,O
blockers,O
(,O
ARBs,MISC
),O
might,O
either,O
increase,O
or,O
reduce,O
the,O
risk,O
of,O
severe,O
or,O
lethal,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
findings,O
from,O
the,O
available,O
obser,O
‐,O
vational,O
studies,O
varied,O
.,O
and,O
summary,O
estimates,O
are,O
urgently,O
need,O
‐,O
ed,O
to,O
elucidate,O
whether,O
these,O
drugs,CRIMINAL_CHARGE
should,O
be,O
suspended,O
during,O
the,O
pandemic,O
.,O
or,O
patients,O
and,O
physicians,O
should,O
be,O
definitely,O
re,O
‐,O
assured,O
.,O
This,O
meta,O
‐,O
analysis,O
of,O
adjusted,O
observational,O
data,O
aimed,O
to,O
summarise,O
the,O
existing,O
evidence,O
on,O
the,O
association,O
between,O
these,O
medications,O
and,O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
.,O
Methods,O
We,O
searched,O
MedLine,ORGANIZATION
.,O
Scopus,ORGANIZATION
and,O
preprint,O
repositories,O
up,O
to,O
8,DATE
June,DATE
2020,DATE
to,O
retrieve,O
cohort,O
or,O
casecontrol,O
studies,O
comparing,O
the,O
risk,O
of,O
severe,O
/,O
fatal,O
COVID,O
‐,O
19,NUMBER
(,O
either,O
mechanical,O
ventilation,O
.,O
inten,O
‐,O
sive,O
care,O
unit,O
admission,O
or,O
death,O
),O
.,O
among,O
hypertensive,O
subjects,O
treated,O
with,O
:,O
(,O
1,NUMBER
),O
ACE,O
inhibitors,O
.,O
(,O
2,NUMBER
),O
ARBs,O
and,O
(,O
3,NUMBER
),O
both,O
.,O
versus,O
untreated,O
subjects,O
.,O
Data,O
were,O
combined,O
using,O
a,O
random,O
‐,O
effect,O
generic,O
inverse,O
variance,O
approach,O
.,O
Results,O
Ten,NUMBER
studies,O
.,O
en,O
‐,O
rolling,O
9890,NUMBER
hypertensive,O
subjects,O
were,O
included,O
in,O
the,O
analyses,O
.,O
Compared,O
with,O
untreated,O
subjects,O
.,O
those,O
using,O
either,O
ACE,O
in,O
‐,O
hibitors,O
or,O
ARBs,MISC
showed,O
a,O
similar,O
risk,O
of,O
severe,O
or,O
lethal,O
COVID,O
‐,O
19,NUMBER
(,O
summary,O
OR,STATE_OR_PROVINCE
:,O
0.90,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.65,NUMBER
to,O
1.26,NUMBER
for,O
ACE,O
in,O
‐,O
hibitors,O
;,O
0.92,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.75,NUMBER
to,O
1.12,NUMBER
for,O
ARBs,MISC
),O
.,O
The,O
results,O
did,O
not,O
change,O
when,O
both,O
drugs,CRIMINAL_CHARGE
were,O
considered,O
together,O
.,O
when,O
death,O
was,O
the,O
outcome,O
and,O
excluding,O
the,O
studies,O
with,O
significant,O
.,O
di,O
‐,O
vergent,O
results,O
.,O
Conclusion,O
The,O
present,DATE
meta,O
‐,O
analysis,O
strongly,O
supports,O
the,O
recommendation,O
of,O
several,O
scientific,O
societies,O
to,O
continue,O
ARBs,O
or,O
ACE,O
inhibitors,O
for,O
all,O
patients,O
.,O
unless,O
other,O
‐,O
wise,O
advised,O
by,O
their,O
physicians,O
who,O
should,O
thus,O
be,O
reassured,O
.,O
employer,O
(,O
s,O
),O
),O
2020,DATE
.,O
Re,O
‐,O
use,O
permitted,O
under,O
CC,O
BY,O
‐,O
NC,STATE_OR_PROVINCE
.,O
No,O
by,O
BMJ,ORGANIZATION
.,O
To,O
cite,O
:,O
Flacco,PERSON
ME,STATE_OR_PROVINCE
.,O
Acuti,O
Martellucci,O
C,O
.,O
Bravi,PERSON
F,O
.,O
print,O
:,O
[,O
please,O
include,O
Day,DURATION
With,O
the,O
spread,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
pandemic,O
.,O
evidence,O
is,O
rapidly,O
accumu,O
‐,O
lating,O
on,O
the,O
risk,O
factors,O
of,O
severe,O
COVID,O
‐,O
19,NUMBER
and,O
death,O
.,O
In,O
the,O
wake,O
of,O
some,O
preliminary,O
.,O
unadjusted,O
reports,O
.14,O
individuals,O
with,O
pre,O
‐,O
existing,O
comorbidities,O
such,O
as,O
hypertension,CAUSE_OF_DEATH
.,O
diabetes,CAUSE_OF_DEATH
and,O
cardiovascular,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
have,O
been,O
identified,O
as,O
those,O
highly,O
vul,O
‐,O
nerable,O
.5,NUMBER
Notably,O
.,O
such,O
chronic,O
conditions,O
frequently,O
require,O
prescription,O
of,O
ACE,O
inhibitors,O
and,O
angiotensin,O
II,NUMBER
receptor,O
block,O
‐,O
ers,O
(,O
ARBs,O
),O
.6,NUMBER
Animal,O
studies,O
showed,O
that,O
ACE,O
inhibitors,O
and,O
ARBs,O
upregulate,O
ACE2,O
expression7,O
and,O
.,O
as,O
coronaviruses,O
bind,O
their,O
tar,O
‐,O
get,O
cells,O
through,O
ACE2,O
.,O
concerns,O
have,O
been,O
expressed,O
that,O
these,O
therapies,O
might,O
facilitate,O
infection,CAUSE_OF_DEATH
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
increase,O
the,O
risk,O
of,O
severe,O
or,O
fatal,O
COVID,O
‐,O
19.6,NUMBER
8,NUMBER
In,O
contrast,O
.,O
it,O
has,O
been,O
suggested,O
that,O
ACE,O
inhibitors,O
and,O
ARBs,O
could,O
benefit,O
infected,O
pa,O
‐,O
tients,O
.,O
as,O
ACE2,O
converts,O
angiotensin,O
II,NUMBER
(,O
with,O
known,O
vasoconstric,O
‐,O
tive,O
.,O
proinflammatory,O
and,O
fibrotic,O
effects,O
),O
into,O
angiotensin,O
17,NUMBER
.,O
which,O
may,O
protect,O
lungs,O
from,O
acute,O
injury,O
.,O
and,O
upregulating,O
ACE2,O
through,O
therapy,O
may,O
enhance,O
this,O
process,O
.9,NUMBER
In,O
this,O
uncertain,O
sce,O
‐,O
nario,O
.,O
some,O
observational,O
studies,O
with,O
multivariable,O
analyses,O
found,O
no,O
association,O
between,O
use,O
of,O
reninangiotensinaldosterone,O
system,O
(,O
RAAS,O
),O
inhibitors,O
and,O
COVID,O
‐,O
19,NUMBER
severity,O
.1016,O
a,O
few,O
studies,O
found,O
a,O
significant,O
reduction,O
in,O
the,O
risk,O
of,O
death,O
or,O
severe,O
dis,O
‐,O
ease17,O
18,NUMBER
and,O
one,NUMBER
study,O
found,O
a,O
increased,O
risk,O
of,O
mechanical,O
ven,O
‐,O
tilation,O
and,O
admission,O
to,O
the,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
.19,NUMBER
The,O
magnitude,O
of,O
the,O
association,O
also,O
varied,O
across,O
studies,O
.,O
which,O
differed,O
for,O
patients,O
characteristics,O
.,O
setting,O
(,O
inpatient,O
or,O
out,O
‐,O
patient,O
),O
.,O
population,O
targeted,O
by,O
serological,O
testing,O
protocols,O
and,O
extent,O
of,O
measured,O
confounding,O
.,O
Summary,O
estimates,O
are,O
ur,O
‐,O
gently,O
needed,O
to,O
elucidate,O
whether,O
these,O
drugs,CRIMINAL_CHARGE
.,O
that,O
are,O
pre,O
‐,O
scribed,O
to,O
tens,O
of,O
millions,O
patients,O
worldwide,O
.20,O
should,O
be,O
sus,O
‐,O
pended,O
during,O
the,O
pandemic,O
.,O
or,O
patients,O
and,O
physicians,O
should,O
be,O
definitely,O
reassured,O
.7,NUMBER
We,O
thus,O
carried,O
out,O
a,O
meta,O
‐,O
analysis,O
to,O
summarise,O
the,O
existing,O
evidence,O
from,O
adjusted,O
analyses,O
on,O
the,O
as,O
‐,O
sociation,O
between,O
RAAS,O
inhibitors,O
and,O
COVID,O
‐,O
19,NUMBER
.,O
Bibliographic,O
search,O
.,O
data,O
extraction,O
and,O
quality,O
We,O
searched,O
MEDLINE,ORGANIZATION
and,O
Sco,O
‐,O
pus,O
databases,O
.,O
up,O
to,O
11,DATE
May,DATE
2020,DATE
.,O
for,O
studies,O
evaluating,O
the,O
risk,O
of,O
severe,O
and,O
/,O
or,O
fatal,O
COVID,O
‐,O
19,NUMBER
among,O
ACE,O
inhibitors,O
and,O
/,O
or,O
ARBs,O
users,O
versus,O
non,O
‐,O
users,O
.,O
The,O
following,O
search,O
strategy,O
was,O
adopt,O
‐,O
ed,O
.,O
without,O
language,O
restrictions,O
:,O
COVID,O
‐,O
19,NUMBER
[,O
Title,O
/,O
Abstract,O
],O
OR,STATE_OR_PROVINCE
Coronavirus,O
[,O
Title,O
/,O
Abstract,O
],O
OR,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
Title,O
/,O
Abstract,O
],O
AND,O
angiotensin,O
*,O
[,O
Title,O
/,O
Abstract,O
],O
.,O
was,O
also,O
screened,O
for,O
additional,O
pertinent,O
papers,O
.,O
In,O
the,O
context,O
of,O
a,O
public,O
health,O
emergency,O
.,O
there,O
is,O
urgency,O
to,O
make,O
research,O
findings,O
available,O
.21,NUMBER
and,O
sev,O
‐,O
eral,O
relevant,O
clinical,O
data,O
have,O
been,O
shared,O
in,O
public,O
preprint,O
repositories,O
:,O
we,O
thus,O
extended,O
the,O
in,O
MedRxiv,O
.,O
Inclusion,O
criteria,O
were,O
:,O
(,O
A,O
),O
cohort,O
or,O
Treatment,O
with,O
ACE,O
inhibitors,O
or,O
ARBs,O
and,O
risk,O
of,O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
:,O
a,O
meta,O
‐,O
analysis,O
Cardiac,MISC
risk,O
fac,O
‐,O
tors,O
and,O
prevention,O
The,O
informed,O
consent,O
was,O
not,O
required,O
.,O
as,O
the,O
study,O
did,O
not,O
enrol,O
human,O
subjects,O
.,O
casecontrol,O
design,O
;,O
(,O
B,O
),O
lab,O
‐,O
oratory,O
confirmation,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
status,O
through,O
PCR,O
assay,O
of,O
nasal,O
or,O
pharyngeal,O
swab,O
specimens,O
;,O
(,O
C,O
),O
available,O
infor,O
‐,O
mation,O
on,O
underlying,O
comorbidities,O
and,O
pharmacological,O
treatments,O
at,O
the,O
time,DATE
of,O
COVID,O
‐,O
19,NUMBER
;,O
and,O
(,O
D,O
),O
data,O
available,O
to,O
compare,O
COVID,O
‐,O
19,NUMBER
severity,O
by,O
RAAS,O
who,O
extracted,O
the,O
study,O
characteristics,O
and,O
measures,O
of,O
effect,O
.,O
contacted,O
(,O
LM,O
),O
.,O
and,O
consensus,O
was,O
achieved,O
through,O
discussion,O
.,O
Individual,O
study,O
quality,O
was,O
as,O
‐,O
sessed,O
using,O
an,O
adapted,O
version,O
of,O
the,O
Newcastle,ORGANIZATION
Ottawa,ORGANIZATION
Quality,ORGANIZATION
Assessment,O
Scale,O
.,O
assessing,O
the,O
comparability,O
across,O
groups,O
for,O
confounding,O
factors,O
.,O
the,O
appropriateness,O
of,O
outcome,O
assessment,O
.,O
length,O
of,O
follow,O
‐,O
up,O
and,O
missing,O
data,O
handling,O
and,O
reporting,O
.22,NUMBER
Data,O
analysis,O
Data,O
were,O
combined,O
using,O
a,O
random,O
‐,O
effect,O
generic,O
inverse,O
variance,O
approach23,O
in,O
order,O
to,O
account,O
for,O
between,O
‐,O
study,O
heterogeneity,O
.,O
Missing,O
SEs,O
were,O
computed,O
from,O
95,PERCENT
%,PERCENT
CIs,O
following,O
standard,O
Cochrane,PERSON
methodology,O
.,O
If,O
a,O
paper,O
reported,O
the,O
results,O
of,O
different,O
multivariable,O
models,O
.,O
the,O
most,O
stringently,O
controlled,O
estimates,O
(,O
those,O
from,O
the,O
model,TITLE
adjusting,O
for,O
more,O
factors,O
),O
were,O
extracted,O
.,O
If,O
different,O
models,O
controlled,O
for,O
the,O
same,O
number,O
of,O
covariates,O
.,O
the,O
model,TITLE
containing,O
the,O
most,O
clinically,O
meaningful,O
covariates,O
was,O
used,O
for,O
the,O
analysis,O
.24,NUMBER
study,O
heterogeneity,O
was,O
quantified,O
using,O
the,O
I2,O
statistic,O
.,O
Potential,O
publication,O
bias,O
was,O
assessed,O
graphically,O
.,O
using,O
funnel,O
plots,O
(,O
displaying,O
the,O
Relative,O
Risks,O
from,O
individual,O
comparisons,O
versus,O
their,O
precision,O
(,O
1,NUMBER
/,O
SE,O
),O
.,O
Given,O
that,O
the,O
total,O
number,O
of,O
publications,O
included,O
for,O
each,O
outcome,O
was,O
<,O
10,NUMBER
.,O
we,O
could,O
not,O
use,O
formal,O
tests,O
for,O
funnel,O
plot,O
asymmetry,O
:,O
in,O
such,O
cases,O
.,O
the,O
power,O
is,O
too,O
low,O
to,O
distinguish,O
chance,O
from,O
real,O
The,O
units,O
of,O
the,O
meta,O
‐,O
analysis,O
were,O
single,O
com,O
‐,O
parisons,O
of,O
:,O
(,O
A,O
),O
ACE,O
inhibitors,O
.,O
(,O
B,O
),O
ARBs,MISC
users,O
and,O
(,O
C,O
),O
both,O
ACE,O
inhibitors,O
Of,O
the,O
553,NUMBER
papers,O
initially,O
retrieved,O
.,O
five,NUMBER
casecon,O
‐,O
trol,O
and,O
five,NUMBER
Overall,O
.,O
the,O
studies,O
included,O
9890,DATE
hypertensive,O
subjects,O
;,O
four,NUMBER
studies,O
included,O
only,O
COVID,O
‐,O
19,NUMBER
symptomatic,O
pa,O
‐,O
tients,O
requiring,O
Europe,LOCATION
.1012,NUMBER
14,DATE
16,DATE
17,DATE
two,NUMBER
in,O
the,O
USA15,O
19,NUMBER
and,O
two,NUMBER
in,O
China,COUNTRY
.13,NUMBER
18,NUMBER
The,O
mean,O
age,O
ranged,O
from,O
58,DURATION
to,DURATION
69,DURATION
years,DURATION
.,O
and,O
the,O
sample,O
size,O
ranged,O
from,O
20517,NUMBER
to,NUMBER
6272.14,NUMBER
The,O
methodological,O
char,O
‐,O
acteristics,O
of,O
the,O
included,O
studies,O
are,O
ascertainment,O
of,O
the,O
ex,O
‐,O
posure,O
and,O
the,O
evaluation,O
of,O
the,O
comparability,O
of,O
subjects,O
were,O
adequate,O
in,O
all,O
studies,O
.,O
while,O
8,NUMBER
out,O
of,O
10,NUMBER
adequately,O
addressed,O
the,O
items,O
pertaining,O
to,O
outcome,O
assessment,O
and,O
follow,O
‐,O
up,O
(,O
length,O
and,O
missing,O
data,O
),O
.,O
One,NUMBER
study,O
had,O
a,O
high,O
risk,O
of,O
misclassification,O
bias,O
.,O
as,O
the,O
proportions,O
of,O
hypertensive,O
subjects,O
treated,O
with,O
ACE,O
inhibitors,O
(,O
16.4,PERCENT
%,PERCENT
),O
or,O
ARBs,O
(,O
13.2,PERCENT
%,PERCENT
),O
were,O
particularly,O
low,O
.19,NUMBER
Risk,O
of,O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
A,O
total,O
of,O
five,NUMBER
studies,O
.,O
enrolling,O
7489,NUMBER
hypertensive,O
patients,O
.,O
were,O
included,O
in,O
the,O
meta,O
‐,O
analysis,O
comparing,O
the,O
risk,O
of,O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
between,O
ACE,O
in,O
‐,O
hibitors,O
users,O
versus,O
non,O
‐,O
or,O
lethal,O
disease,CAUSE_OF_DEATH
was,O
comparable,O
among,O
treated,O
and,O
untreated,O
patients,O
(,O
summary,O
OR,STATE_OR_PROVINCE
:,O
0.90,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.65,NUMBER
to,O
1.26,NUMBER
),O
.,O
Two,NUMBER
studies,O
showed,O
significant,O
results,O
.,O
with,O
opposite,O
di,O
‐,O
rection,O
.,O
The,O
first,ORDINAL
included,O
682,NUMBER
hypertensive,O
subjects,O
and,O
showed,O
an,O
increased,O
risk,O
of,O
severe,O
illness,CAUSE_OF_DEATH
among,O
the,O
112,NUMBER
patients,O
treat,O
‐,O
ed,O
with,O
ACE,O
inhibitors,O
.19,NUMBER
The,DATE
second,DATE
enrolled,O
105,NUMBER
hypertensive,O
subjects,O
and,O
reported,O
a,O
lower,O
risk,O
among,O
the,O
38,NUMBER
treated,O
pa,O
‐,O
tients,O
.17,NUMBER
Excluding,O
one,NUMBER
or,O
both,O
of,O
these,O
studies,O
did,O
not,O
change,O
the,O
results,O
.,O
which,O
remained,O
non,O
‐,O
significant,O
(,O
all,O
p,O
>,O
0.05,NUMBER
),O
.,O
Five,NUMBER
studies,O
.,O
enrolling,O
7462,NUMBER
hypertensive,O
subjects,O
.,O
were,O
included,O
in,O
the,O
meta,O
‐,O
analysis,O
comparing,O
the,O
risk,O
of,O
severe,O
illness,CAUSE_OF_DEATH
All,O
of,O
them,O
showed,O
non,O
‐,O
significant,O
differences,O
between,O
treated,O
and,O
un,O
‐,O
treated,O
patients,O
.,O
with,O
a,O
summary,O
OR,STATE_OR_PROVINCE
of,O
0.92,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
When,O
the,O
above,O
antihypertensive,O
treatments,O
were,O
considered,O
together,O
(,O
five,NUMBER
studies,O
.,O
enrolling,O
11,NUMBER
334,NUMBER
hypertensive,O
patients,O
),O
.10,DATE
11,DATE
14,DATE
15,DATE
19,DATE
the,O
risk,O
of,O
developing,O
severe,O
COVID,O
‐,O
19,NUMBER
was,O
again,O
comparable,O
be,O
‐,O
tween,O
treated,O
and,O
untreated,O
patients,O
Risk,O
of,O
death,O
from,O
COVID,O
‐,O
19,NUMBER
The,O
risk,O
of,O
death,O
among,O
RAAS,O
inhibitors,O
users,O
versus,O
non,O
‐,O
users,O
was,O
compared,O
in,O
four,NUMBER
studies,O
.,O
including,O
a,O
total,O
of,O
2412,DATE
and,O
ARBs,O
users,O
.,O
versus,O
non,O
users,O
.,O
in,O
predicting,O
:,O
(,O
1,NUMBER
),O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
(,O
presence,O
of,O
either,O
ICU,O
admission,O
.,O
mechanical,O
ventila,O
‐,O
tion,O
or,O
death,O
),O
and,O
(,O
2,NUMBER
),O
lethal,O
COVID,O
‐,O
19,NUMBER
.,O
When,O
a,O
study,O
only,O
report,O
‐,O
ed,O
separate,O
estimates,O
for,O
ACE,O
inhibitors,O
or,O
ARBs,MISC
users,O
.,O
or,O
for,O
the,O
different,O
outcomes,O
included,O
in,O
the,O
definition,O
of,O
severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
(,O
eg,O
.,O
ICU,O
admission,O
and,O
mechanical,O
ventilation,O
separately,O
),O
.,O
the,O
overall,O
estimate,O
of,O
risk,O
was,O
computed,O
from,O
the,O
separate,O
relative,O
risks,O
using,O
the,O
fixed,O
‐,O
effect,O
model,TITLE
for,O
generic,O
inverse,O
variance,O
outcomes,O
.24,NUMBER
All,O
meta,O
‐,O
analyses,O
were,O
performed,O
us,O
‐,O
ing,O
RevMan,O
software,O
.,O
V.,O
5.3,NUMBER
(,O
The,O
Cochrane,ORGANIZATION
Collaboration,ORGANIZATION
.,O
2019,DATE
),O
.,O
Cardiac,O
risk,O
factors,O
and,O
prevention,O
Characteristics,O
of,O
the,O
in,O
‐,O
cluded,O
studies,O
Study,O
design,O
de,O
Abajo11,O
The,O
Lancet,O
Giorgi,PERSON
Rossi12,PERSON
No,O
.,O
of,O
Mean,O
age,O
Severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
Logistic,O
regression,O
(,O
ICU,O
and,O
death,O
),O
.,O
adjusted,O
for,O
age,O
.,O
gender,O
and,O
comorbidities,O
.,O
venti,O
‐,O
lation,O
.,O
ICU,O
and,O
death,O
),O
;,O
(,O
2,NUMBER
),O
death,O
.,O
Logistic,MISC
regression,O
adjusted,O
for,O
age,O
.,O
gender,O
and,O
comorbidities,O
Severe,O
COVID,O
‐,O
19,NUMBER
Logistic,O
re,O
‐,O
gression,O
adjusted,O
for,O
age,O
.,O
gender,O
.,O
variables,O
),O
and,O
Cox,ORGANIZATION
proportion,O
‐,O
al,O
hazard,O
analysis,O
adjusted,O
for,O
age,O
.,O
gender,O
and,O
Charlson,PERSON
Se,PERSON
‐,PERSON
vere,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
Logistic,O
regression,O
(,O
dyspnoea,CAUSE_OF_DEATH
.,O
resp,O
.,O
rate,O
adjusted,O
for,O
gender,O
and,O
SaO2,O
93,PERCENT
%,PERCENT
.,O
mech,O
.,O
Severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
Logistic,MISC
regression,MISC
(,O
ICU,O
and,O
death,O
),O
.,O
adjusted,O
forage,O
.,O
gender,O
and,O
comorbidities,O
.,O
Severe,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
Logistic,O
regression,O
(,O
ICU,O
and,O
mech,O
.,O
adjusted,O
for,O
age,O
.,O
gender,O
and,O
comorbidities,O
.,O
Se,O
‐,O
vere,O
/,O
lethal,O
COVID,O
‐,O
19,NUMBER
Analysis,O
propensity,O
(,O
mech,O
.,O
ventilation,O
.,O
ICU,O
score,O
‐,O
matched,O
for,O
and,O
death,O
),O
.,O
age,O
.,O
gender,O
.,O
race,O
.,O
BMI,O
.,O
smoke,O
.,O
co,O
‐,O
morbidities,O
and,O
Clin,ORGANIZATION
Infect,ORGANIZATION
Cox,ORGANIZATION
proportional,O
hazard,O
analysis,O
ad,O
‐,O
justed,O
for,O
age,O
.,O
gender,O
and,O
comorbidities,O
.,O
Circ,PERSON
Res,PERSON
Analysis,PERSON
propensity,O
score,O
‐,O
matched,O
for,O
age,O
.,O
gender,O
.,O
comorbidities,O
and,O
in,O
‐,O
hospital,O
therapy,O
.,O
Extracted,O
outcome,O
(,O
s,O
),O
Method,O
for,O
adjustment,O
Lo,O
‐,O
gistic,O
regression,O
adjusted,O
for,O
age,O
.,O
race,O
.,O
comorbidities,O
and,O
*,O
Cas,O
‐,O
es,O
were,O
COVID,O
‐,O
19,NUMBER
patients,O
;,O
controls,O
were,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
negative,O
sub,O
‐,O
jects,O
extracted,O
from,O
primary,O
healthcare,O
databases,O
:,O
as,O
such,O
.,O
the,O
number,O
of,O
hypertensive,O
subjects,O
includes,O
both,O
cases,O
and,O
controls,O
and,O
is,O
higher,O
than,O
the,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Number,O
of,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
among,O
only,O
those,O
with,O
hypertension,CAUSE_OF_DEATH
.,O
Included,O
only,O
in,O
sensitivity,O
analyses,O
.,O
ARBs,MISC
.,O
Angiotensin,O
recep,O
‐,O
tor,O
blockers,O
;,O
ICU,O
.,O
intensive,O
care,O
unit,O
;,O
mech.,O
.,O
mechanical,O
;,O
NR,O
.,O
not,O
reported,O
;,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
severe,O
acute,O
respiratory,O
syndrome,O
coro,O
‐,O
navirus,O
2,NUMBER
.,O
the,O
Newcastle,ORGANIZATION
Ottawa,ORGANIZATION
Scale,ORGANIZATION
de,O
Abajo11,O
Giorgi,PERSON
Rossi12,PERSON
hypertensive,O
subjects,O
.10,NUMBER
12,DATE
16,DATE
18,DATE
Overall,DATE
.,O
no,O
differences,O
in,O
risk,O
emerged,O
between,O
the,O
two,NUMBER
groups,O
.,O
with,O
a,O
summary,O
OR,STATE_OR_PROVINCE
of,O
from,O
China,COUNTRY
.,O
enrolling,O
1128,DATE
hospitalised,O
hypertensive,O
patients,O
.,O
showed,O
a,O
sig,O
‐,O
nificant,O
risk,O
reduction,O
among,O
treated,O
subjects18,O
;,O
when,O
its,O
re,O
‐,O
sults,O
were,O
excluded,O
from,O
the,O
analyses,O
.,O
the,O
overall,O
estimates,O
did,O
not,O
change,O
(,O
pooled,O
OR,O
0.95,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.76,NUMBER
to,O
1.18,NUMBER
),O
.,O
Another,O
study25,O
assessed,O
the,O
risk,O
of,O
death,O
among,O
ACE,O
inhibitors,O
/,O
ARBs,O
users,O
versus,O
non,O
users,O
and,O
was,O
initially,O
included,O
in,O
the,O
meta,O
‐,O
analysis,O
.,O
Howev,O
‐,O
er,O
.,O
this,O
study,O
was,O
later,O
retracted26,O
;,O
thus,O
.,O
it,O
was,O
excluded,O
from,O
the,O
main,O
analyses,O
and,O
included,O
into,O
a,O
sensitivity,O
analysis,O
:,O
with,O
or,O
without,O
the,O
study,O
.,O
the,O
summary,O
estimate,O
did,O
not,O
change,O
(,O
pooled,O
OR,O
0.85,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.81,NUMBER
to,O
1.03,NUMBER
),O
.,O
Two,NUMBER
main,O
findings,O
emerge,O
from,O
the,O
present,DATE
meta,O
‐,O
analysis,O
.,O
which,O
included,O
the,O
adjusted,O
estimates,O
of,O
10,NUMBER
observational,O
studies,O
and,O
No,O
.,O
of,O
infected,O
Cardiac,O
risk,O
factors,O
and,O
prevention,O
No,O
.,O
of,O
OR,STATE_OR_PROVINCE
(,O
95,PERCENT
%,PERCENT
CI,O
),O
P,O
value,O
versus,O
non,O
‐,O
users,O
.,O
ARBs,MISC
.,O
angiotensin,O
receptor,O
blockers,O
.,O
1,NUMBER
.,O
Severe,O
/,O
fatal,O
COVID,O
‐,O
19,NUMBER
*,O
(,O
in,O
users,O
vs,O
non,O
users,O
),O
:,O
ACE,O
inhibitors,O
ARBs,O
only10,O
1315,DATE
19,DATE
2,DATE
.,O
Death,O
from,O
COVID,O
‐,O
19,NUMBER
(,O
in,O
users,O
vs,O
non,O
users,O
),O
:,O
a.,O
Main,O
analysis,O
:,O
b.,O
Sen,O
‐,O
sitivity,O
analysis,O
:,O
All,O
meta,O
‐,O
analyses,O
are,O
based,O
on,O
a,O
generic,O
in,O
‐,O
verse,O
variance,O
approach,O
.,O
*,O
Including,O
admission,O
into,O
intensive,O
care,O
unit,O
.,O
need,O
for,O
mechanical,O
ventilation,O
or,O
Including,O
one,NUMBER
re,O
‐,O
tracted,O
study,O
.25,NUMBER
26,NUMBER
ARBs,MISC
.,O
angiotensin,O
receptor,O
blockers,O
;,O
RAAS,O
.,O
reninangiotensinaldosterone,O
.,O
almost,O
10,NUMBER
000,NUMBER
hypertensive,O
sub,O
‐,O
jects,O
:,O
first,ORDINAL
.,O
no,O
significant,O
differences,O
in,O
the,O
risk,O
of,O
develop,O
‐,O
ing,O
severe,O
or,O
fatal,O
COVID,O
‐,O
19,NUMBER
were,O
observed,O
between,O
the,O
subjects,O
treated,O
with,O
either,O
ACE,O
inhibitors,O
or,O
ARBs,MISC
.,O
as,O
compared,O
with,O
non,O
‐,O
users,O
.,O
Second,ORDINAL
.,O
and,O
importantly,O
.,O
the,O
results,O
did,O
not,O
change,O
after,O
the,O
exclusion,O
of,O
the,O
three,NUMBER
studies,O
.,O
which,O
reported,O
either,O
a,O
sig,O
‐,O
nificantly,O
higher,O
or,O
lower,O
risk,O
of,O
severe,O
illness,CAUSE_OF_DEATH
among,O
treated,O
patients,O
.,O
The,O
present,DATE
findings,O
provide,O
solid,O
evidence,O
from,O
prop,O
‐,O
erly,O
adjusted,O
estimates,O
across,O
different,O
countries,O
on,O
the,O
absence,O
of,O
risk,O
from,O
RAAS,O
inhibitors,O
treatment,O
during,O
the,O
pandemic,O
.,O
strongly,O
supporting,O
the,O
statements,O
of,O
several,O
experts27,O
28,NUMBER
and,O
scientific,O
societies,O
.,O
including,O
the,O
European,ORGANIZATION
Medicines,ORGANIZATION
Agency,ORGANIZATION
.29,O
the,O
European,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Cardiology30,ORGANIZATION
and,O
the,O
American,NATIONALITY
Heart,O
Asso,O
‐,O
ciation,O
.31,O
who,O
recommend,O
continuation,O
of,O
ARBs,O
or,O
ACE,O
inhibitors,O
medication,O
.,O
Although,O
the,O
present,DATE
findings,O
do,O
not,O
support,O
the,O
hy,O
‐,O
pothesis,O
of,O
a,O
beneficial,O
effect,O
from,O
therapy,O
during,O
the,O
necessary,O
time,O
required,O
for,O
randomised,O
data,O
to,O
come,O
.,O
patients,O
and,O
physi,O
‐,O
cians,O
can,O
be,O
reassured,O
.,O
Some,O
limitations,O
should,O
be,O
considered,O
when,O
interpreting,O
the,O
present,DATE
findings,O
.,O
First,ORDINAL
.,O
two,NUMBER
meta,O
‐,O
analyses,O
showed,O
an,O
intermediate,O
‐,O
to,O
‐,O
high,O
level,O
of,O
heterogeneity,O
.,O
However,O
.,O
a,O
certain,O
large,O
variation,O
in,O
terms,O
of,O
setting,O
and,O
baseline,O
patients,O
characteristics,O
.,O
Also,O
.,O
when,O
the,O
analyses,O
were,O
repeated,O
adopting,O
a,O
fixed,O
approach,O
.,O
none,O
of,O
the,O
results,O
substantially,O
differed,O
(,O
ex,O
‐,O
cept,O
for,O
CIs,O
.,O
which,O
were,O
typically,O
tighter,O
),O
.,O
Second,ORDINAL
.,O
although,O
all,O
studies,O
(,O
with,O
a,O
single,O
exception,O
),O
13,NUMBER
provided,O
analyses,O
at,O
least,O
adjusted,O
for,O
versus,O
non,O
‐,O
users,O
.,O
age,O
.,O
gender,O
and,O
several,O
underly,O
‐,O
ing,O
comorbidities,O
.,O
some,O
extent,O
of,O
residual,O
confounding,O
can,O
not,O
be,O
completely,O
ruled,O
out,O
.,O
as,O
for,O
any,O
observational,O
study,O
.32,NUMBER
Third,ORDINAL
.,O
as,O
shown,O
in,O
the,O
funnel,O
plots,O
in,O
the,O
more,O
than,O
five,NUMBER
studies,O
.,O
thus,O
it,O
was,O
not,O
possible,O
to,O
perform,O
a,O
meaningful,O
evaluation,O
of,O
publica,O
‐,O
tion,O
bias,O
.,O
However,O
.,O
given,O
the,O
public,O
health,O
relevance,O
of,O
these,O
data,O
.,O
it,O
is,O
unlikely,O
that,O
non,O
‐,O
significant,O
findingswith,O
reassur,O
‐,O
ing,O
implicationshave,O
been,O
withheld,O
.,O
Rather,O
.,O
it,O
is,O
certain,O
that,O
large,O
dataset,O
will,O
be,O
available,O
soon,O
.,O
Given,O
the,O
urgency,O
for,O
mil,O
‐,O
lions,O
of,O
patients,O
.,O
we,O
decided,O
not,O
to,O
wait,O
.,O
but,O
the,O
present,DATE
meta,O
‐,O
analysis,O
will,O
have,O
to,O
be,O
updated,O
as,O
inclusion,O
bias,O
.,O
due,O
to,O
the,O
presence,O
of,O
multiple,O
effect,O
estimates,O
that,O
can,O
be,O
extracted,O
from,O
individual,O
studies,O
.33,O
is,O
likely,O
to,O
be,O
low,O
.,O
as,O
only,O
one,NUMBER
of,O
the,O
in,O
‐,O
cluded,O
studies,O
reported,O
more,O
than,O
an,O
adjusted,O
estimate,O
.18,O
and,O
the,O
results,O
of,O
the,O
meta,O
‐,O
analysis,O
including,O
the,O
alternate,O
estimate,O
of,O
effect,O
were,O
unchanged,O
(,O
pooled,O
OR,STATE_OR_PROVINCE
of,O
death,O
0.88,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
0.68,NUMBER
to,O
1.13,NUMBER
),O
.,O
Acknowledging,O
these,O
caveats,O
.,O
the,O
present,DATE
meta,O
‐,O
analysis,O
.,O
based,O
on,O
10,NUMBER
studies,O
and,O
almost,O
10,NUMBER
000,NUMBER
hypertensive,O
subjects,O
.,O
did,O
not,O
find,O
any,O
association,O
between,O
COVID,O
‐,O
19,NUMBER
severity,O
or,O
mortality,O
and,O
treatment,O
with,O
ARBs,MISC
.,O
ACE,O
inhibitors,O
or,O
both,O
.,O
strongly,O
sup,O
‐,O
porting,O
the,O
recommendation,O
of,O
several,O
scientific,O
societies,O
to,O
continue,O
ARBs,O
or,O
ACE,O
inhibitors,O
medication,O
for,O
all,O
patients,O
.,O
un,O
‐,O
less,O
otherwise,O
advised,O
by,O
their,O
physicians,O
.,O
who,O
should,O
thus,O
be,O
reassured,O
.,O
RC,O
.,O
LGM,O
and,O
LaM,O
),O
.,O
conduct,O
(,O
MEF,O
.,O
CAM,O
.,O
FB,O
.,O
GP,O
.,O
RC,O
.,O
AM,O
.,O
RM,O
.,O
LGM,O
),O
and,O
reporting,O
(,O
MEF,O
.,O
FB,O
.,O
GP,O
.,O
AM,O
.,O
RM,O
.,O
LGM,O
and,O
LM,O
),O
of,O
the,O
present,DATE
work,O
.,O
users,O
versus,O
non,O
‐,O
users,O
.,O
ARBs,MISC
.,O
angiotensin,O
receptor,O
blockers,O
.,O
users,O
.,O
ARBs,MISC
.,O
angiotensin,O
receptor,O
blockers,O
.,O
subjects,O
treated,O
with,O
RAAS,O
inhibitors,O
versus,O
untreated,O
subjects,O
.,O
overall,O
and,O
by,O
drug,O
class,O
Cardiac,MISC
risk,O
factors,O
and,O
prevention,O
Key,O
mes,O
‐,O
sages,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
positive,O
subjects,O
showed,O
an,O
increased,O
mortality,O
and,O
morbidity,O
among,O
hypertensive,O
patients,O
.,O
who,O
were,O
frequently,O
treated,O
with,O
ACE,O
inhibitors,O
or,O
angiotensin,O
receptor,O
blockers,O
(,O
ARBs,MISC
),O
.,O
Recently,DATE
.,O
some,O
observational,O
studies,O
with,O
multivariable,O
analyses,O
found,O
no,O
association,O
between,O
these,O
medications,O
and,O
COVID,O
‐,O
19,NUMBER
severity,O
.,O
a,O
few,O
studies,O
found,O
a,O
signifi,O
‐,O
cant,O
reduction,O
in,O
the,O
risk,O
of,O
death,O
or,O
severe,O
disease,CAUSE_OF_DEATH
and,O
one,NUMBER
study,O
found,O
a,O
increased,O
risk,O
of,O
mechanical,O
ventilation,O
and,O
admis,O
‐,O
sion,O
to,O
the,O
intensive,O
care,O
unit,O
.,O
The,O
magnitude,O
of,O
the,O
association,O
also,O
varied,O
across,O
studies,O
.,O
which,O
differed,O
for,O
patients,O
charac,O
‐,O
teristics,O
.,O
setting,O
(,O
inpatient,O
or,O
outpatient,O
),O
.,O
population,O
targeted,O
by,O
serological,O
testing,O
protocols,O
and,O
extent,O
of,O
measured,O
confound,O
‐,O
ing,O
.,O
What,O
might,O
this,O
study,O
add,O
?,O
This,O
meta,O
‐,O
analysis,O
is,O
based,O
on,O
10,NUMBER
adjusted,O
observational,O
studies,O
(,O
enrolling,O
almost,O
10,NUMBER
000,NUMBER
hypertensive,O
subjects,O
),O
.,O
from,O
different,O
countries,O
.,O
and,O
provides,O
the,O
first,ORDINAL
summary,O
estimate,O
on,O
the,O
associ,O
‐,O
ation,O
between,O
ACE,O
inhibitors,O
or,O
ARBs,O
use,O
and,O
COVID,O
‐,O
19,NUMBER
severity,O
or,O
mortality,O
.,O
All,O
analyses,O
showed,O
a,O
comparable,O
risk,O
of,O
severe,O
or,O
fa,O
‐,O
tal,O
illness,CAUSE_OF_DEATH
among,O
treated,O
and,O
untreated,O
subjects,O
.,O
either,O
consid,O
‐,O
ering,O
ACE,O
inhibitors,O
or,O
ARBs,MISC
separately,O
.,O
or,O
combined,O
.,O
How,O
might,O
this,O
impact,O
on,O
clinical,O
practice,O
?,O
Given,O
that,O
ACE,O
inhibitors,O
and,O
ARBs,O
are,O
prescribed,O
to,O
tens,O
of,O
millions,O
patients,O
worldwide,O
.,O
summary,O
estimates,O
were,O
strongly,O
needed,O
to,O
elucidate,O
whether,O
these,O
drugs,CRIMINAL_CHARGE
should,O
be,O
suspended,O
dur,O
‐,O
ing,O
the,O
pandemic,O
.,O
or,O
patients,O
and,O
physicians,O
should,O
be,O
definitely,O
reassured,O
.,O
These,O
findings,O
strongly,O
support,O
the,O
recommendation,O
of,O
several,O
scientific,O
societies,O
to,O
continue,O
ARBs,O
or,O
ACE,O
inhibitors,O
medication,O
for,O
all,O
patients,O
.,O
unless,O
otherwise,O
advised,O
by,O
their,O
physicians,O
.,O
Competing,O
interests,O
None,O
declared,O
.,O
Patient,O
and,O
pub,O
‐,O
lic,O
involvement,O
Patients,O
and,O
/,O
or,O
the,O
public,O
were,O
not,O
involved,O
in,O
the,O
design,O
.,O
or,O
conduct,O
.,O
or,O
reporting,O
.,O
or,O
dissemination,O
plans,O
of,O
this,O
research,O
.,O
Patient,O
consent,O
for,O
publication,O
Not,O
required,O
.,O
Ethics,O
approval,O
The,O
study,O
complies,O
with,O
the,O
Declaration,O
of,O
Hel,O
‐,O
sinki,O
.,O
As,O
a,O
meta,O
‐,O
analysis,O
.,O
the,O
protocol,O
and,O
study,O
did,O
not,O
re,O
‐,O
quire,O
the,O
approval,O
from,O
Ethics,ORGANIZATION
Committee,ORGANIZATION
.,O
Data,O
availability,O
statement,O
Data,O
are,O
available,O
on,O
reasonable,O
request,O
.,O
All,O
data,O
properly,O
cited,O
.,O
appropriate,O
credit,O
is,O
given,O
.,O
any,O
changes,O
made,O
in,O
‐,O
dicated,O
.,O
and,O
the,O
use,O
1,NUMBER
Yang,PERSON
X,PERSON
.,O
Yu,O
Y,O
.,O
Xu,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
outcomes,O
of,O
critically,O
ill,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
single,O
‐,O
centered,O
.,O
retrospective,O
.,O
observational,O
study,O
.,O
Lancet,O
Respir,O
Med,O
2020,DATE
;,O
8:47581,NUMBER
.,O
What,O
is,O
already,O
known,O
on,O
this,O
subject,O
?,O
Some,O
preliminary,O
.,O
unadjusted,O
reports,O
on,O
severe,O
acute,O
2,NUMBER
Guan,O
WJ,O
.,O
ZY,O
N,O
.,O
Hu,O
Y,O
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
coronavirus,O
dis,O
‐,O
ease,O
2019,DATE
in,O
China,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
.,O
3,NUMBER
Guo,PERSON
T,PERSON
.,O
Fan,O
Y,O
.,O
Chen,PERSON
M,O
.,O
et,O
al,O
.,O
Cardiovascular,O
implications,O
of,O
fatal,O
outcomes,O
of,O
patients,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
JAMA,O
Cardiol,O
2020,DATE
.,O
4,NUMBER
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
Important,O
Lessons,O
From,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Outbreak,O
in,O
China,COUNTRY
:,O
Summa,O
‐,O
ry,O
of,O
a,O
Report,O
of,O
72,NUMBER
314,NUMBER
Cases,O
From,O
the,O
Chinese,NATIONALITY
Center,O
for,O
Dis,O
‐,O
ease,O
Control,O
and,O
Prevention,O
.,O
JAMA,O
2020,DATE
5,NUMBER
Yang,PERSON
J,PERSON
.,O
Zheng,O
Y,O
.,O
Gou,PERSON
X,PERSON
.,O
et,O
al,O
.,O
Prevalence,O
of,O
comorbidities,O
and,O
its,O
effects,O
in,O
6,NUMBER
Karakiu,O
‐,O
lakis,O
G,O
.,O
Roth,PERSON
M.,O
Are,O
patients,O
with,O
hypertension,CAUSE_OF_DEATH
and,O
diabetes,CAUSE_OF_DEATH
mel,O
‐,O
litus,O
at,O
increased,O
risk,O
for,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
?,O
Lancet,O
Respir,O
Med,O
2020,DATE
.,O
ldosterone,O
system,O
7,NUMBER
Vaduganathan,O
M,O
.,O
Vardeny,PERSON
O,PERSON
.,O
Michel,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Renin,O
‐,O
Angiotensin,O
‐,O
A,O
inhibitors,O
in,O
patients,O
with,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
.,O
8,NUMBER
Zheng,O
Y,O
‐,O
Y,O
.,O
Ma,O
Y,O
‐,O
T,O
.,O
Zhang,PERSON
J,O
‐,O
Y,O
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
and,O
the,O
cardiovascular,O
system,O
.,O
Nat,PERSON
Rev,PERSON
9,NUMBER
Bavishi,O
C,O
.,O
Maddox,PERSON
TM,O
.,O
Messerli,PERSON
FH,O
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
10,NUMBER
Bravi,PERSON
F,O
.,O
Flacco,PERSON
ME,STATE_OR_PROVINCE
.,O
Carradori,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Predictors,O
of,O
severe,O
or,O
lethal,O
COVID,O
‐,O
19,NUMBER
.,O
including,O
angiotensin,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,O
II,NUMBER
receptor,O
blockers,O
.,O
in,O
a,O
sample,O
of,O
infected,O
Italian,NATIONALITY
citizens,O
.,O
Plos,O
One,NUMBER
2020,DATE
;,O
15,NUMBER
:,O
e0235248,O
.,O
11,NUMBER
de,O
Abajo,O
FJ,O
.,O
Rodrguez,PERSON
‐,O
Martn,PERSON
S,PERSON
.,O
Lerma,PERSON
V,O
.,O
et,O
al,O
.,O
Use,O
of,O
renin,O
‐,O
angiotensin,O
‐,O
aldosterone,O
system,O
inhibitors,O
and,O
risk,O
of,O
COVID,O
‐,O
19,NUMBER
requiring,O
admission,O
to,O
hospital,O
:,O
a,O
case,O
‐,O
population,O
study,O
.,O
Lancet,O
2020,DATE
;,O
395:170514,NUMBER
.,O
12,NUMBER
Giorgi,PERSON
Rossi,PERSON
P,O
.,O
Marino,PERSON
M,O
.,O
Formisano,PERSON
D,PERSON
.,O
et,O
al,O
.,O
Characteristics,O
and,O
outcomes,O
of,O
a,O
cohort,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
patients,O
in,O
the,O
province,O
of,O
Reggio,ORGANIZATION
Emilia,ORGANIZATION
.,O
Italy,COUNTRY
.,O
MedRxiv2020,O
.,O
13,NUMBER
Liu,O
Y,O
.,O
Huang,PERSON
F,O
.,O
Xu,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Anti,O
‐,O
Hypertensive,O
angiotensin,O
II,NUMBER
receptor,O
blockers,O
associated,O
to,O
mitigation,O
of,O
disease,CAUSE_OF_DEATH
severity,O
in,O
elderly,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
14,NUMBER
Mancia,PERSON
G,PERSON
.,O
Rea,PERSON
F,O
.,O
Ludergnani,PERSON
M,O
.,O
et,O
al,O
.,O
Renin,O
‐,O
Angiotensin,O
‐,O
Aldos,O
‐,O
terone,O
system,O
blockers,O
and,O
the,O
risk,O
of,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
2020,DATE
;,O
382:243140,NUMBER
.,O
15,NUMBER
Reynolds,ORGANIZATION
HR,ORGANIZATION
.,O
Adhikari,PERSON
S,O
.,O
Pulgarin,O
C,O
.,O
et,O
al,O
.,O
Renin,O
‐,O
Angiotensin,O
‐,O
A,O
ldosterone,O
system,O
inhibitors,O
and,O
risk,O
of,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
2020,DATE
.,O
16,NUMBER
Tedeschi,PERSON
S,O
.,O
Giannella,PERSON
M,O
.,O
Bartoletti,PERSON
M,O
.,O
et,O
al,O
.,O
Clinical,O
impact,O
of,O
renin,O
‐,O
angiotensin,O
system,O
inhibitors,O
on,O
in,O
‐,O
hospital,O
mor,O
‐,O
tality,O
of,O
patients,O
with,O
hypertension,CAUSE_OF_DEATH
hospitalized,O
17,NUMBER
Bean,O
D,O
.,O
Kraljevic,PERSON
Z,PERSON
.,O
Searle,PERSON
T,O
.,O
et,O
al,O
.,O
Treatment,O
with,O
ACE,O
‐,O
inhibitors,O
is,O
associated,O
with,O
less,O
severe,O
disease,CAUSE_OF_DEATH
with,O
SARS,O
‐,O
Covid,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
in,O
a,O
multi,O
‐,O
site,O
UK,COUNTRY
acute,O
Hospital,O
18,NUMBER
Zhang,O
P,O
.,O
Zhu,PERSON
L,PERSON
.,O
Cai,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Association,O
of,O
inpatient,O
use,O
of,O
angiotensin,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,O
II,NUMBER
receptor,O
blockers,O
with,O
mortality,O
among,O
patients,O
with,O
hypertension,CAUSE_OF_DEATH
hospitalized,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Circ,O
Res,O
2020,DATE
.,O
19,NUMBER
Mehta,ORGANIZATION
N,ORGANIZATION
.,O
Kalra,PERSON
A,O
.,O
Nowacki,PERSON
AS,STATE_OR_PROVINCE
.,O
et,O
al,O
.,O
Association,O
of,O
use,O
of,O
angiotensin,O
‐,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,O
II,NUMBER
receptor,O
blockers,O
with,O
testing,O
positive,O
for,O
coronavirus,O
dis,O
‐,O
ease,O
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
JAMA,O
Cardiol,O
2020,DATE
.,O
20,NUMBER
WHO,O
.,O
COVID,O
‐,O
19,NUMBER
and,O
the,O
use,O
of,O
angiotensin,O
‐,O
converting,O
enzyme,O
inhibitors,O
and,O
receptor,O
blockers,O
‐,O
Scientific,O
brief,O
.,O
WHO,O
.,O
2020,DATE
.,O
21,NUMBER
Carr,ORGANIZATION
D.,ORGANIZATION
Sharing,ORGANIZATION
re,O
‐,O
search,O
data,O
and,O
findings,O
relevant,O
to,O
the,O
novel,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
outbreak,O
.,O
secondary,O
sharing,O
research,O
data,O
and,O
findings,O
relevant,O
to,O
the,O
coronavirus,O
‐,O
c,O
ovid,O
‐,O
19,NUMBER
/,O
o,O
pen,O
‐,O
data,O
22,NUMBER
Wells,O
G,O
.,O
Shea,PERSON
B,O
.,O
OConnell,O
D,O
.,O
et,O
al,O
.,O
The,O
Newcastle,ORGANIZATION
‐,O
Ottawa,CITY
scale,O
(,O
NOS,O
),O
for,O
as,O
‐,O
sessing,O
the,O
quality,O
of,O
nonrandomised,O
studies,O
in,O
meta,O
‐,O
analyses,O
.,O
secondary,O
the,O
Newcastle,ORGANIZATION
‐,O
Ottawa,CITY
scale,O
(,O
NOS,O
),O
for,O
assessing,O
the,O
quality,O
of,O
nonrandomised,O
studies,O
in,O
meta,O
‐,O
23,NUMBER
Manzoli,O
L,O
.,O
Flacco,PERSON
ME,O
.,O
Boccia,PERSON
S,O
.,O
et,O
al,O
.,O
Generic,O
versus,O
brand,O
‐,O
name,O
drugs,CRIMINAL_CHARGE
used,O
in,O
car,O
‐,O
diovascular,O
diseases,CAUSE_OF_DEATH
.,O
Eur,MISC
J,O
Epidemiol,O
2016,DATE
;,O
31:35168,NUMBER
.,O
24,NUMBER
Manfre,O
‐,O
dini,O
R,O
.,O
Fabbian,MISC
F,MISC
.,O
Cappadona,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Daylight,TIME
saving,O
time,O
and,O
acute,O
25,NUMBER
Mehra,PERSON
MR,PERSON
.,O
Desai,PERSON
SS,O
.,O
Kuy,PERSON
S,O
.,O
et,O
al,O
.,O
Cardiovascular,O
dis,O
‐,O
ease,O
.,O
drug,O
therapy,O
.,O
and,O
mortality,O
in,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
.,O
26,NUMBER
Mehra,PERSON
MR,PERSON
.,O
Desai,PERSON
SS,O
.,O
Kuy,PERSON
S,O
.,O
et,O
al,O
.,O
Retraction,O
:,O
cardiovascular,O
disease,CAUSE_OF_DEATH
.,O
drug,O
therapy,O
.,O
and,O
mortality,O
in,O
Covid,O
‐,O
19,DATE
2020,DATE
.,O
N,O
Engl,PERSON
J,PERSON
Med,O
.,O
27,NUMBER
Kuster,ORGANIZATION
GM,ORGANIZATION
.,O
Osswald,PERSON
S.,O
Switching,O
antihypertensive,O
therapy,O
in,O
times,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
why,O
we,O
should,O
wait,O
for,O
the,O
evidence,O
.,O
Eur,O
Heart,O
J,O
2020,DATE
;,O
41:1857,NUMBER
.,O
28,NUMBER
Kuster,ORGANIZATION
GM,ORGANIZATION
.,O
Pfister,O
O,O
.,O
Burkard,PERSON
T,O
.,O
et,O
al,O
.,O
SARS,O
‐,O
CoV2,O
:,O
should,O
inhibitors,O
of,O
the,O
renin,O
‐,O
angiotensin,O
system,O
be,O
withdrawn,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
?,O
Eur,O
Heart,O
J,O
29,NUMBER
European,NATIONALITY
Medicines,ORGANIZATION
Agency,ORGANIZATION
.,O
Ema,O
advises,O
continued,O
use,O
of,O
medicines,O
for,O
hy,O
‐,O
pertension,O
.,O
heart,O
or,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
during,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
2020,DATE
.,O
Available,O
:,O
hypertension,CAUSE_OF_DEATH
‐,O
h,O
eart,O
‐,O
kidney,O
‐,O
d,O
isease,O
‐,O
during,O
‐,O
covid,O
‐,O
19,NUMBER
‐,O
p,O
andemic,O
[,O
Accessed,O
20,DATE
Apr,DATE
30,DATE
European,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Cardi,ORGANIZATION
‐,O
ology,O
.,O
Position,O
statement,O
of,O
the,O
ESC,ORGANIZATION
Council,ORGANIZATION
on,O
hypertension,CAUSE_OF_DEATH
on,O
ACE,O
‐,O
inhibitors,O
and,O
angiotensin,O
receptor,O
blockers,O
.,O
2020,DATE
.,O
Avail,O
‐,O
able,O
:,O
Cardiac,O
risk,O
factors,O
and,O
prevention,O
physician?utm,O
_,O
cam,O
‐,O
paign,O
=,O
sciencenews19,NUMBER
‐,O
20,NUMBER
&,O
utm_source,O
=,O
s,O
cience,O
‐,O
news,O
&,O
utm,O
_,O
medium,O
=,O
phd,O
‐,O
link,O
&,O
u,O
tm_content,O
=,O
phd03,NUMBER
‐,O
17,NUMBER
‐,O
2,NUMBER
0,NUMBER
32,NUMBER
Thomas,PERSON
LE,PERSON
.,O
Bonow,PERSON
RO,PERSON
.,O
Pencina,PERSON
MJ,ORGANIZATION
.,O
Understanding,O
observational,O
treatment,O
comparisons,O
in,O
the,O
set,O
‐,O
ting,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
JAMA,PERSON
Cardiol,PERSON
to,O
se,O
‐,O
lective,O
inclusion,O
of,O
trial,O
effect,O
estimates,O
:,O
empirical,O
study,O
.,O
BMJ,O
Open,O
statement,O
‐,O
o,O
f,O
‐,O
the,O
‐,O
e,O
sc,O
‐,O
council,O
‐,O
on,O
‐,O
hypertension,CAUSE_OF_DEATH
‐,O
on,O
‐,O
ace,O
‐,O
in,O
‐,O
hibitors,O
‐,O
and,O
‐,O
ang,O
[,O
Accessed,O
31,NUMBER
American,ORGANIZATION
Hearth,ORGANIZATION
Association,ORGANIZATION
.,O
Pa,STATE_OR_PROVINCE
‐,O
tients,O
taking,O
ACE,O
‐,O
i,O
and,O
Arbs,MISC
who,O
contract,O
COVID,O
‐,O
19,NUMBER
should,O
contin,O
‐,O
ue,O
treatment,O
.,O
unless,O
otherwise,O
advised,O
by,O
their,O
physician,TITLE
.,O
2020,DATE
.,O
contract,O
‐,O
c,O
ovid,O
‐,O
19,NUMBER
‐,O
s,O
hould,O
‐,O
continue,O
‐,O
treatment,O
‐,O
unless,O
‐,O
otherwise,O
‐,O
advised,O
‐,O
by,O
‐,O
their,O
‐,O
